头颈癌带蒂皮瓣重建患者的输血情况
本研究回顾136例头颈带蒂皮瓣重建患者(64例SCAIF、57例PM、15例SM),其中40例(29.4%)接受输血。输血与手术或内科并发症无关联,且Hct<21与Hct<27两种输血阈值在住院时间、皮瓣存活及并发症上无差异。
要点
- 带蒂皮瓣患者输血率29.4%,PM皮瓣输血率47.4%高于SCAIF的17.2%和SM的13.3%
- 输血与感染、裂开、瘘或内科并发症无差异
- Hct<21与Hct<27输血阈值结局无差异,支持更保守的输血策略
核心结论
- 输血与头颈带蒂皮瓣重建术后手术或内科并发症无关联。
- Hct<21与Hct<27两种输血阈值在住院时间、皮瓣存活和并发症上无差异,提示更保守的输血阈值可能不会引发不良并发症。
研究设计与样本
- 回顾性研究,纳入136例头颈带蒂皮瓣重建患者:64例锁骨上动脉岛状皮瓣(SCAIF)、57例胸大肌(PM)皮瓣、15例颏下(SM)皮瓣。
- 采用多因素logistic回归分析校正相关术前和围手术期因素。
- 证据等级:4。
主要发现
- 136例中40例(29.4%)接受输血。
- 输血前平均红细胞压积(Hct)为24.3%±0.5%,输注2.65±0.33单位,输血后Hct升高5.0%±0.6%。
- 输血率:PM 47.4%、SCAIF 17.2%、SM 13.3%(P<0.005)。
- PM重建患者输血量有更高趋势(PM 2.89±0.47单位、SC 2.18±0.28单位、SM 2.00±0.0单位),且输血发生更晚(术后4.9±1.3天 vs 其他皮瓣2.4±0.1天;P=0.08)。
- 感染、裂开、瘘或内科并发症无差异。
关键数值与推荐
- 输血前平均Hct 24.3%±0.5%,输注2.65±0.33单位,输血后Hct升高5.0%±0.6%。
- 输血率PM 47.4%、SCAIF 17.2%、SM 13.3%(P<0.005)。
- Hct<21与Hct<27输血阈值在住院时间、皮瓣存活、内科/皮瓣相关并发症上无差异。
临床怎么用
- 头颈带蒂皮瓣重建患者可采用更保守的输血阈值,不必因担心并发症而放宽输血指征。
- PM皮瓣患者输血率较高且输血发生较晚,围手术期需关注其输血需求。
局限性
- 证据等级为4,属回顾性研究。
- 样本量有限(n=136),SM皮瓣仅15例。
- 作者指出需进一步研究头颈皮瓣重建的输血实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Blood product utilization is monitored to prevent unnecessary transfusions. Head-and-neck pedicled flap reconstruction transfusion-related outcomes were assessed. METHODS: One hundred and thirty-six pedicled flap patients were reviewed: 64 supraclavicular artery island flaps (SCAIF), 57 pectoralis major (PM) flaps, and 15 submental (SM) flaps. Outcome parameters included flap-related complications, medical complications, length of stay (LOS), and flap survival. Multivariable logistic regression analyses were performed. Multivariable logistic regression analyses were performed to adjust for relevant pre- and perioperative factors. RESULTS: Of all head-and-neck pedicled flap patients included in our analyses (n = 136), 40 (29.4%) received blood transfusions. The average pretransfusion hematocrit (Hct) was 24.3% ± 0.5%, with 2.65 ± 0.33 units transfused and a posttransfusion Hct increase of 5.0% ± 0.6%. Transfusion rates differed with PM (47.4%), SCAIF (17.2%), and SM (13.3%) flaps (P < 0.005). Patients undergoing PM reconstruction trended toward higher transfusion requirements (PM 2.89 ± 0.47 units, SC 2.18 ± 0.28 units, and SM 2.00 ± 0.0 units), with transfusion occurring later in the postoperative course (4.9 ± 1.3 days vs. 2.4 ± 0.1 days for all other flaps; P = 0.08). Infection, dehiscence, fistula, or medical complications were not different. Transfusion thresholds of Hct < 21 versus Hct < 27 exhibited no difference in LOS, flap-survival, or medical/flap-related complications. CONCLUSION: Transfusion is not associated with surgical or medical morbidity following head and neck pedicled flap reconstruction. There were no differences in outcomes between transfusion triggers of Hct < 21 versus Hct < 27, suggesting that a more conservative transfusion trigger may not precipitate adverse patient complications. Our data recapitulate findings in free flap patients and warrant further investigation of transfusion practices in head and neck flap reconstruction. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:E409-E415, 2018.
引用
- Abt NB, Puram SV, Sinha S, et al. Transfusion in Head and Neck Cancer Patients Undergoing Pedicled Flap Reconstruction. Laryngoscope. 2018. PMID: 30247764. doi:10.1002/lary.27393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。